Clinical trial
Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed…
NCT00028899 · Children's Oncology Group, Other · Completed
Key facts
| NCT number | NCT00028899 |
|---|---|
| Title | Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes |
| Official title | A Dose Finding Study of the Safety of Gemtuzumab Ozogamicin Combined With Conventional Chemotherapy for Patients With Relapsed or Refractory Acute Myeloid Leukemia |
| Lead sponsor | Children's Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | asparaginase, cytarabine, gemtuzumab ozogamicin, mitoxantrone hydrochloride |
| Enrollment | 47 |
| Start date | Jul 1, 2002 |
| Primary completion | Sep 1, 2006 |
| Completion | Mar 1, 2012 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 20, 2014 |
| Countries | Australia, Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: